<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39405443</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Remdesivir-associated survival outcomes among immunocompromised patients hospitalized for COVID-19: real-world evidence from the Omicron dominant era.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ciae510</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciae510</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with immunocompromising conditions are at an increased risk for coronavirus disease 2019 (COVID-19)-related hospitalizations and mortality. Randomized clinical trials provide limited enrollment, if any, to inform outcomes of such patients treated with remdesivir.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using the US PINC AI Healthcare Database, we identified adult patients with immunocompromising conditions, hospitalized for COVID-19 between December 2021 and February 2024. Primary outcome was all-cause inpatient mortality examined in propensity score (PS) matched patients in remdesivir versus non-remdesivir groups. Subgroup analyses were performed for patients with cancer, hematologic malignancies, and solid organ/hematopoietic stem cell transplant recipients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 28,966 patients included in the study, 16,730 (58%) received remdesivir during first two days of hospitalization. After PS matching, 8,822 patients in remdesivir and 8,822 patients in non-remdesivir group were analyzed. Remdesivir was associated with a significantly lower mortality among patients with no supplemental oxygen (aHR [95% CI]: 14-day, 0.73 [0.62-0.86]; 28-day, 0.79 [0.68-0.91]) and among those with supplemental oxygen (14-day, 0.75 [0.67-0.85]; 28-day, 0.78 [0.70-0.86]). Remdesivir was also associated with lower mortality in subgroups of patients with cancer, hematological malignancies (including leukemia, lymphoma, and multiple myeloma), and solid organ/hematopoietic stem cell transplantation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this large cohort of patients with immunocompromising conditions hospitalized for COVID-19, remdesivir was associated with significant improvement in survival, including patients with varied underlying immunocompromising conditions. The integration of current real-world evidence into clinical guideline recommendations can inform clinical communities to optimize treatment decisions in the evolving COVID-19 era, extending beyond the conclusion of the public health emergency declaration.</AbstractText><CopyrightInformation>Â© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mozaffari</LastName><ForeName>Essy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandak</LastName><ForeName>Aastha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5653-435X</Identifier><AffiliationInfo><Affiliation>Certara, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0001-8376-8709</Identifier><AffiliationInfo><Affiliation>Baylor University Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baylor Scott &amp; White Heart and Vascular Hospital, Dallas, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baylor Scott &amp; White The Heart Hospital, Plano, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baylor Scott &amp; White Research Institute, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chima-Melton</LastName><ForeName>Chidinma</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Tele-ICU Inc, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pipeline Health System, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8534-2012</Identifier><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Alpesh N</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0002-9790-0245</Identifier><AffiliationInfo><Affiliation>University of California, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sax</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalil</LastName><ForeName>Andre C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-6489-6294</Identifier><AffiliationInfo><Affiliation>University of Nebraska Medical Center, Omaha, Nebraska, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">data science</Keyword><Keyword MajorTopicYN="N">hematological malignancy</Keyword><Keyword MajorTopicYN="N">immunocompromised</Keyword><Keyword MajorTopicYN="N">leukemia</Keyword><Keyword MajorTopicYN="N">lymphoma</Keyword><Keyword MajorTopicYN="N">multiple myeloma</Keyword><Keyword MajorTopicYN="N">propensity score</Keyword><Keyword MajorTopicYN="N">real-world data</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">transplantation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39405443</ArticleId><ArticleId IdType="doi">10.1093/cid/ciae510</ArticleId><ArticleId IdType="pii">7823126</ArticleId></ArticleIdList></PubmedData></PubmedArticle>